Ocuphire Pharma Announces First Patient Enrolled in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis

Ocuphire Pharma Announces Expansion of Global Patents for Nyxol® and $1.7 Million NIH Grants for APX3330 Program

H.C. Wainwright 6th Annual Israel Conference

Nov 12, 2020 • 3:30pm EST

Ocuphire Pharma to Host Key Opinion Leader Event on Nyxol® and APX3330

Nov 9, 2020 • 10:00am EST